



Contact: Robert J. Naylor
Tel. 017919-621 733
Email: r.j.naylor@avipero.com

FOR IMMEDIATE PRESS RELEASE

Wednesday, 11 January 2012

AVIPERO Issued 2 major UK Patents on targeting Beta1 Integrin for Tissue Repair and Related Methods.

EDINBURGH, SCOTLAND-----AVIPERO (Registered in Scotland SC353945) announced today that it has been issued two patents from the U.K. Intellectual Property Office claiming methods for use of beta1 integrin for tissue repair AND assay methods for identifying compounds targeting beta1 integrin for use in tissue repair. The patents GB2478082 and GB2460009 have priority date of 26 February, 2007 and will remain in force until 26 February 2028.

About AVIPERO Ltd.

AVIPERO Ltd (Registered in Scotland SC353945) is a private biopharmaceutical company established in 2009. Avipero is focused on the development of novel therapeutics for unmet clinical needs, characterised by a loss of cells and tissues. This includes conditions such as Parkinson's disease (PD), chronic obstructive pulmonary disease (COPD), arthritis and age related cell decline. AVIPERO has a proprietary first-in-class therapeutic platform covered by a strong intellectual property portfolio.

About beta1 integrin

Integrins are membrane spanning proteins facilitating the two way communication between the inside and outside of a cell. Integrins have the capacity to bind a multitude of molecules both inside and outside of the cell. The binding of these molecules results in the transmission of information into and out of the cell, which can influence a host of different cellular functions, including the cells metabolic activity and energy.

Of the many types of integrin receptors, the beta1 integrin is by far the most ubiquitous allowing cells to detect a vast array of stimuli ranging from toxins, protein hormones, neurotransmitters and macromolecules. There have been numerous publications documenting a potential role of beta1 integrin in tissue development and repair in several tissue types. It is clear that beta1 integrin plays a crucial role during postnatal skin development and wound healing, with the loss of epithelial beta1 integrin causing extensive skin blistering and wound healing defects.

Forward Looking Statements

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, AVIPERO's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which AVIPERO may

develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and AVIPERO's dependence on collaborative partners and contract research organizations. These factors should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.

FOR FURTHER INFORMATION PLEASE CONTACT:

Robert J. Naylor
AVIPERO Ltd
Director,
07919-621-733
info@avipero.com
www.avipero.com